RALEIGH, N.C.--(BUSINESS WIRE)--NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of leading experts in nephrology to its newly formed Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to NephroGenex as it continues to develop the Company’s novel drug candidates to treat kidney disease.
